Gene · 7150
Papers4,103
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
421 to 440 of 4,103
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Siglec-7 glyco-immune binding mAbs or NK cell engager biologics induce potent antitumor immunity against ovarian cancers. | Sci Adv | 2023 | 37910620 | PubTator, text mining | PubMed |
| Camptothecin-based prodrug nanomedicines for cancer therapy. | Nanoscale | 2023 | 37909755 | PubTator, text mining | PubMed |
| Current Application of Nanoparticle Drug Delivery Systems to the Treatment of Anaplastic Thyroid Carcinomas. | Int J Nanomedicine | 2023 | 37904863 | PubTator, text mining | PubMed |
| Mechanisms of genotoxicity and proteotoxicity induced by the metalloids arsenic and antimony. | Cell Mol Life Sci | 2023 | 37904059 | PubTator, text mining | PubMed |
| Clinical value of chemiluminescence method for detection of antinuclear antibody profiles. | World J Clin Cases | 2023 | 37901001 | PubTator, text mining | PubMed |
| The chromatin network helps prevent cancer-associated mutagenesis at transcription-replication conflicts. | Nat Commun | 2023 | 37898641 | PubTator, text mining | PubMed |
| Topoisomerase Inhibitors Increase Episomal DNA Expression by Inducing the Integration of Episomal DNA in Hepatic Cells. | Pharmaceutics | 2023 | 37896219 | PubTator, text mining | PubMed |
| Prospects of Topoisomerase Inhibitors as Promising Anti-Cancer Agents. | Pharmaceuticals (Basel) | 2023 | 37895927 | PubTator, text mining | PubMed |
| Usnic Acid Derivatives Inhibit DNA Repair Enzymes Tyrosyl-DNA Phosphodiesterases 1 and 2 and Act as Potential Anticancer Agents. | Genes (Basel) | 2023 | 37895279 | PubTator, text mining | PubMed |
| Investigating the Metabolism of Plants Germinated in Heavy Water, D2O, and H218O-Enriched Media Using High-Resolution Mass Spectrometry. | Int J Mol Sci | 2023 | 37895078 | PubTator, text mining | PubMed |
| Chemical Insights into Oxidative and Nitrative Modifications of DNA. | Int J Mol Sci | 2023 | 37894920 | PubTator, text mining | PubMed |
| The RELT Family of Proteins: An Increasing Awareness of Their Importance for Cancer, the Immune System, and Development. | Biomedicines | 2023 | 37893069 | PubTator, text mining | PubMed |
| Atypical genotoxicity of carcinogenic nickel(II): Linkage to dNTP biosynthesis, DNA-incorporated rNMPs, and impaired repair of TOP1-DNA crosslinks. | J Biol Chem | 2023 | 37890780 | PubTator, text mining | PubMed |
| Splicing alterations in pancreatic ductal adenocarcinoma: a new molecular landscape with translational potential. | J Exp Clin Cancer Res | 2023 | 37880792 | PubTator, text mining | PubMed |
| Regulation of self-renewal and senescence in primitive mesenchymal stem cells by Wnt and TGFβ signaling. | Stem Cell Res Ther | 2023 | 37880755 | PubTator, text mining | PubMed |
| Functional genomics reveals an off-target dependency of drug synergy in gastric cancer therapy. | bioRxiv | 2023 | 37873383 | PubTator, text mining | PubMed |
| Mutational topography reflects clinical neuroblastoma heterogeneity. | Cell Genom | 2023 | 37868040 | PubTator, text mining | PubMed |
| The fragmentomic property of plasma cell-free DNA enables the non-invasive detection of diabetic nephropathy in patients with diabetes mellitus. | Front Endocrinol (Lausanne) | 2023 | 37867508 | PubTator, text mining | PubMed |
| Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports. | Heliyon | 2023 | 37860534 | PubTator, text mining | PubMed |
| An overview of the past decade of bufalin in the treatment of refractory and drug-resistant cancers: current status, challenges, and future perspectives. | Front Pharmacol | 2023 | 37860119 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7150/papers?page=22